Nissay Asset Management Corp Japan ADV Sells 35,678 Shares of Moderna, Inc. (NASDAQ:MRNA)

Nissay Asset Management Corp Japan ADV trimmed its holdings in Moderna, Inc. (NASDAQ:MRNA) by 47.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 40,077 shares of the company’s stock after selling 35,678 shares during the quarter. Nissay Asset Management Corp Japan ADV’s holdings in Moderna were worth $1,608,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB lifted its holdings in shares of Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after acquiring an additional 587 shares during the last quarter. Compass Planning Associates Inc bought a new stake in shares of Moderna in the 4th quarter worth approximately $37,000. Venturi Wealth Management LLC lifted its holdings in shares of Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after acquiring an additional 664 shares during the last quarter. Crowley Wealth Management Inc. bought a new stake in shares of Moderna in the 4th quarter worth approximately $41,000. Finally, Itau Unibanco Holding S.A. lifted its holdings in shares of Moderna by 51.2% in the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company’s stock worth $42,000 after acquiring an additional 343 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on MRNA shares. Morgan Stanley lowered their price target on shares of Moderna from $39.00 to $32.00 and set an “equal weight” rating for the company in a report on Wednesday, April 9th. Citigroup started coverage on shares of Moderna in a report on Thursday, March 13th. They set a “neutral” rating and a $40.00 price target for the company. The Goldman Sachs Group lowered shares of Moderna from a “buy” rating to a “neutral” rating and lowered their price target for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Royal Bank of Canada lowered their price target on shares of Moderna from $32.00 to $28.00 and set a “sector perform” rating for the company in a report on Friday, May 2nd. Finally, JPMorgan Chase & Co. lowered their price target on shares of Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a report on Friday, March 21st. Four equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $53.95.

Moderna Price Performance

NASDAQ:MRNA opened at $24.86 on Friday. The firm’s 50-day moving average price is $27.87 and its 200-day moving average price is $35.44. The company has a market capitalization of $9.61 billion, a PE ratio of -2.68 and a beta of 1.99. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $170.47.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.92) by $0.40. The firm had revenue of $108.00 million for the quarter, compared to the consensus estimate of $130.35 million. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The company’s revenue was down 35.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($3.07) EPS. Equities analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.